Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 7/20 | 0.60 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 4/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13667974 | 0.82 | GRIN2B (0.49) | GRIN2BCETPCHRM2CHRM1CHRM3 | |
| SCHEMBL2106792 | 0.80 | MIF (0.61) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| 3-Methoxybenxyl Isothiocyanate SCHEMBL1551644 | 0.79 | MIF (0.64) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL483536 | 0.77 | MIF (0.74) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL23922832 | 0.76 | GRIN2B (0.47) | GRIN2BCETPCHRM2CHRM1CHRM3 | |
| SCHEMBL31286285 | 0.76 | GRIN2B (0.47) | GRIN2BCETPCHRM2CHRM1CHRM3 | |
| SCHEMBL13913424 | 0.76 | CHRM2 (0.45) | GRIN2BCETPCHRM2CHRM1CHRM3 | |
| SCHEMBL5009648 | 0.76 | DAO (0.55) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL2340843 | 0.76 | MIF (1.00) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL178310 | 0.74 | CHRM2 (0.55) | GRIN2BCETPCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET (FR) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | MC4R, MC3R, MC1R | MIF 277/4885TRPA1 601/4885ALDH1A1 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.